More information: Sergio Escamilla et al, Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients, Alzheimer's & Dementia (2024). DOI: 10.1002/alz.14125 ...

submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 ...

Another class of medication helps with the symptoms of Alzheimer’s disease. Memantine is an N-methyl D-aspartate (NMDA) antagonist sold under the brand name Namenda. It is used to treat middle ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue.

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...

Common neurodegenerative changes in glaucoma and Alzheimer's disease. Retinal amyloid-β ... Acetylcholinesterase inhibitors and NMDA receptor modulators may have a neuroprotective role in ...

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...